South African drugmaker Adcock Ingram has announced the appointment of Kevin Wakeford (pictured) as Chief Executive Officer, with immediate effect. 22 April 2014
The US subsidiary of Japanese drug major Astellas Pharma announced that Jeffrey Bloss has been promoted to the position of senior vice president, medical affairs Americas, Astellas Scientific and Medical Affairs (ASMA), effective April 1. Dr Bloss will serve as a member of the Astellas US management committee. 16 April 2014
New Haven Pharmaceuticals, a privately held specialty pharmaceuticals company, today announced the appointment of Larry Dillaha, to the newly-created position of Executive Vice President Operations. 2 April 2014
Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced the full-time appointment of James Noble as chief executive officer. 26 March 2014
German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit. 26 March 2014
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has announced the appointment of Giles Platford as Head of Commercial Operations, Emerging Markets. 19 March 2014
UK-based company NeRRe Therapeutics, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, has announced the appointment of Ian Nicholson as Chief Business Officer (CBO). 19 March 2014
Spherix Incorporated (NASDAQ: SPEX) have announced that Frank Reiner has joined the company as vice president of
licensing, where he will report to chief executive Anthony Hayes and play a key role in the company's licensing efforts. 19 March 2014
Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike Sullivan to the position of president. 18 March 2014
Australian product development company Clinical Network Services (CNS) has launched a new UK office headed by Paul Cronin who joins as UK Director and Director, Business Development. 10 March 2014
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024